Related Experiment Video
Updated: Jun 13, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Prevention of parenteral nutrition-associated liver disease: lipid minimization
M Petrea Cober1, Daniel H Teitelbaum
1Department of Pharmacy, University of Michigan Hospitals and Health Centers, and CS Mott Children's Hospital, Ann Arbor, Michigan, USA. mcober@umich.edu
Purpose Of Review:
The cause of parenteral nutrition-associated liver disease (PNALD) is unknown. Evidence over the past decade has suggested soybean oil-based intravenous emulsions are a contributing factor to the development of PNALD.
Recent Findings:
This review details the historical and scientific rationale, which associates intravenous lipid emulsion administration and PNALD. The article then reviews our own group's experience with lipid restriction and the reversal of PNALD in neonates on long-term parenteral nutrition. Finally, a clinical approach to restricting soybean-based intravenous lipid emulsions in parenteral nutrition is given.
Summary:
An association between intravenous lipid emulsion administration and the development of PNALD seems probable. Strategies to reduce lipid emulsions or develop new, nonsoybean-based lipid emulsions should be considered.
Related Concept Videos
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Atherosclerosis III: Management
